Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06571721 · ClinicalTrials.gov registry record · NA

The Effects of Topical Almond Oil and Tretinoin on Facial Wrinkles

A NA study of Wrinkle and Pigmentation, sponsored by Integrative Skin Science and Research.

Recruiting
Registry status
NA
Development phase
90
Enrollment target
1
Study location

NCT06571721: Recruiting NA study of Wrinkle and Pigmentation, sponsored by Integrative Skin Science and Research.

NCT06571721 is a NA study of Wrinkle and Pigmentation that is actively recruiting participants, run by Integrative Skin Science and Research. The registered enrollment target is 90 participants, below the 117-participant average among 25 other Wrinkle trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06571721, a NA study of Wrinkle and Pigmentation, is actively recruiting participants, sponsored by Integrative Skin Science and Research.

RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

Investigate the topical use of almond oil, almond oil augmented with 0.5% vitamin E, 0.025% tretinoin oil augmented with castor oil on the appearance of facial fine lines and wrinkles, pigmentation, hydration, trans-epidermal water loss, and sebum excretion rate.

Interventions

  • OTHER Topical Product: Almond Oil
  • OTHER Topical Product: Almond oil augmented with 0.5% Vitamin E
  • OTHER Topical Product: 0.025% Tretinoin oil augmented with castor oil

Study Locations (1)

California

  • Integrative Research Institute - Sacramento

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2024-07-22
Est. Completion 2025-07-22
Phase NA

What NCT06571721 shows while recruiting

NCT06571721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 117-participant average among 25 other Wrinkle trials with a reported enrollment target (23% lower).

The record links to 5 conditions, with Wrinkle appearing as the primary indexed condition, and to 3 interventions - of which Topical Product: Almond Oil is the first listed.

NCT06571721 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06571721 about?

NCT06571721 is a clinical study titled "The Effects of Topical Almond Oil and Tretinoin on Facial Wrinkles". Investigate the topical use of almond oil, almond oil augmented with 0.5% vitamin E, 0.025% tretinoin oil augmented with castor oil on the appearance of facial fine lines and wrinkles, pigmentation, hydration, trans-epidermal water loss, and sebum excretion rate.

What is the current status of trial NCT06571721?

This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2024-07-22. Estimated completion is 2025-07-22.

What conditions does trial NCT06571721 study?

This clinical trial studies the following conditions: Wrinkle, Pigmentation, Collagen Degeneration, Elastic Skin, Sebum Deficiency.

What interventions are being tested in trial NCT06571721?

The interventions under investigation include: Topical Product: Almond Oil (OTHER), Topical Product: Almond oil augmented with 0.5% Vitamin E (OTHER), Topical Product: 0.025% Tretinoin oil augmented with castor oil (OTHER).

Who is sponsoring clinical trial NCT06571721?

This trial is sponsored by Integrative Skin Science and Research, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06571721 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wrinkle

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06571721's enrollment target sits among peer trials

90 9th of 25 higher than 17 of 25 other Wrinkle trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Wrinkle trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06571721, the US trial registry maintained by the National Library of Medicine. NCT06571721 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.